These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38880932)

  • 1. Effects of the phosphodiesterase 2 inhibitor BI 474121 on central nervous system cyclic guanosine monophosphate concentrations: Translational studies.
    van Kraaij S; Goeldner RG; Rosenbrock H; Groeneveld GJ; Kremer P; Schaible J; Zambori J; Schultheis C
    Br J Clin Pharmacol; 2024 Oct; 90(10):2517-2528. PubMed ID: 38880932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I, randomized, proof-of-clinical-mechanism study assessing the pharmacokinetics and pharmacodynamics of the oral PDE9A inhibitor BI 409306 in healthy male volunteers.
    Boland K; Moschetti V; Dansirikul C; Pichereau S; Gheyle L; Runge F; Zimdahl-Gelling H; Sand M
    Hum Psychopharmacol; 2017 Jan; 32(1):. PubMed ID: 28120486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of phosphodiesterase (1B, 2A, 9A and 10A) inhibitors on central nervous system cyclic nucleotide levels in rats and mice.
    Chen J; Zook D; Crickard L; Tabatabaei A
    Neurochem Int; 2019 Oct; 129():104471. PubMed ID: 31121256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Novel Phosphodiesterase 9A Inhibitor BI 409306 Increases Cyclic Guanosine Monophosphate Levels in the Brain, Promotes Synaptic Plasticity, and Enhances Memory Function in Rodents.
    Rosenbrock H; Giovannini R; Schänzle G; Koros E; Runge F; Fuchs H; Marti A; Reymann KG; Schröder UH; Fedele E; Dorner-Ciossek C
    J Pharmacol Exp Ther; 2019 Dec; 371(3):633-641. PubMed ID: 31578258
    [No Abstract]   [Full Text] [Related]  

  • 5. Phosphodiesterase-2 inhibitor reverses corticosterone-induced neurotoxicity and related behavioural changes via cGMP/PKG dependent pathway.
    Xu Y; Pan J; Chen L; Zhang C; Sun J; Li J; Nguyen L; Nair N; Zhang H; O'Donnell JM
    Int J Neuropsychopharmacol; 2013 May; 16(4):835-47. PubMed ID: 22850435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclic GMP-mediated memory enhancement in the object recognition test by inhibitors of phosphodiesterase-2 in mice.
    Lueptow LM; Zhan CG; O'Donnell JM
    Psychopharmacology (Berl); 2016 Feb; 233(3):447-56. PubMed ID: 26525565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, tolerability and pharmacokinetics of the phosphodiesterase 2 inhibitor BI 474121: An overview of phase I randomized trials in healthy volunteers.
    Schaible J; Scholz A; Goeldner RG; Yamamura N
    J Psychopharmacol; 2024 Sep; 38(9):807-817. PubMed ID: 39262288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphodiesterase 2 and Its Isoform A as Therapeutic Targets in the Central Nervous System Disorders.
    Metkar SK; Yan Y; Lu Y; Lu J; Zhu X; Du F; Xu Y
    CNS Neurol Disord Drug Targets; 2024; 23(8):941-955. PubMed ID: 37855295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-in-human study assessing safety, tolerability and pharmacokinetics of BI 409306, a selective phosphodiesterase 9A inhibitor, in healthy males.
    Moschetti V; Boland K; Feifel U; Hoch A; Zimdahl-Gelling H; Sand M
    Br J Clin Pharmacol; 2016 Nov; 82(5):1315-1324. PubMed ID: 27378314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphodiesterase 2 and 5 inhibition attenuates the object memory deficit induced by acute tryptophan depletion.
    van Donkelaar EL; Rutten K; Blokland A; Akkerman S; Steinbusch HW; Prickaerts J
    Eur J Pharmacol; 2008 Dec; 600(1-3):98-104. PubMed ID: 18957291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The roles of phosphodiesterase 2 in the central nervous and peripheral systems.
    Zhang C; Yu Y; Ruan L; Wang C; Pan J; Klabnik J; Lueptow L; Zhang HT; O'Donnell JM; Xu Y
    Curr Pharm Des; 2015; 21(3):274-90. PubMed ID: 25159070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased levels of guanosine 3', 5'-monophosphate (cGMP) in cerebrospinal fluid (CSF) are associated with cognitive decline and amyloid pathology in Alzheimer's disease.
    Ugarte A; Gil-Bea F; García-Barroso C; Cedazo-Minguez Á; Ramírez MJ; Franco R; García-Osta A; Oyarzabal J; Cuadrado-Tejedor M
    Neuropathol Appl Neurobiol; 2015 Jun; 41(4):471-82. PubMed ID: 25488891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes.
    Castro LR; Verde I; Cooper DM; Fischmeister R
    Circulation; 2006 May; 113(18):2221-8. PubMed ID: 16651469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Phosphodiesterase-2 in Psychiatric and Neurodegenerative Disorders.
    Zhang C; Lueptow LM; Zhang HT; O'Donnell JM; Xu Y
    Adv Neurobiol; 2017; 17():307-347. PubMed ID: 28956338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphodiesterase-2 inhibitor reverses post-traumatic stress induced fear memory deficits and behavioral changes via cAMP/cGMP pathway.
    Chen L; Liu K; Wang Y; Liu N; Yao M; Hu J; Wang G; Sun Y; Pan J
    Eur J Pharmacol; 2021 Jan; 891():173768. PubMed ID: 33271150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TAK-915, a phosphodiesterase 2A inhibitor, ameliorates the cognitive impairment associated with aging in rodent models.
    Nakashima M; Suzuki N; Shiraishi E; Iwashita H
    Behav Brain Res; 2019 Dec; 376():112192. PubMed ID: 31521738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential regulation of C-type natriuretic peptide-induced cGMP and functional responses by PDE2 and PDE3 in failing myocardium.
    Moltzau LR; Meier S; Aronsen JM; Afzal F; Sjaastad I; Skomedal T; Osnes JB; Levy FO; Qvigstad E
    Naunyn Schmiedebergs Arch Pharmacol; 2014 May; 387(5):407-17. PubMed ID: 24424715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydrolysis of N-methyl-D-aspartate receptor-stimulated cAMP and cGMP by PDE4 and PDE2 phosphodiesterases in primary neuronal cultures of rat cerebral cortex and hippocampus.
    Suvarna NU; O'Donnell JM
    J Pharmacol Exp Ther; 2002 Jul; 302(1):249-56. PubMed ID: 12065724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective phosphodiesterase 5 inhibition does not reduce propofol sedation requirements but affects speed of recovery and plasma cyclic guanosine 3',5'-monophosphate concentrations in healthy volunteers.
    Engelhardt T; MacDonald J; Galley HF; Webster NR
    Anesth Analg; 2005 Oct; 101(4):1050-1053. PubMed ID: 16192518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphodiesterase-2 is up-regulated in human failing hearts and blunts β-adrenergic responses in cardiomyocytes.
    Mehel H; Emons J; Vettel C; Wittköpper K; Seppelt D; Dewenter M; Lutz S; Sossalla S; Maier LS; Lechêne P; Leroy J; Lefebvre F; Varin A; Eschenhagen T; Nattel S; Dobrev D; Zimmermann WH; Nikolaev VO; Vandecasteele G; Fischmeister R; El-Armouche A
    J Am Coll Cardiol; 2013 Oct; 62(17):1596-606. PubMed ID: 23810893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.